Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.

British journal of haematology - 1 Feb 2022

Zhang Sicong, Zhang Tingting, Liu Hengqi, Zhao Jing, Zhou Haifei, Su Xiaoxing, Liu Xianming, Li Lanfang, Qiu Lihua, Qian Zhengzi, Zhou Shiyong, Gong Wenchen, Meng Bin, Ren Xiubao, He Jin, Wang Xianhuo, Zhang Huilai

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established. In the present study, 17 tumour biopsy and 38 plasma samples from 38 patients with high-intermediate/high-risk DLBCL were evaluated at baseline. Longitudinal blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to beta 2-Microglobulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Circulating Tumor DNA

Share to Combined Modality Therapy

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Grading

Share to Neoplasm Staging

Source

Identifiers

PMID: 34664256
DOI: 10.1111/bjh.17894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.PMID 34664256Read ↗

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read ↗

Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.Semantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Diffuse large B-cell lymphoma genotyping on the liquid biopsy.Semantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.Semantic proximity Read ↗

Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA.Semantic proximity Read ↗

Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.